{"gene":"POLR3A","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2011,"finding":"POLR3A encodes the largest (RPC1/RPC155) catalytic subunit of RNA Polymerase III; recessive missense and insertion mutations in POLR3A cause a significant decrease in POLR3A protein levels in patient fibroblasts and brain tissue, with greater reduction in cerebral white matter than cortex, establishing POLR3A as essential for CNS myelination.","method":"Immunoblotting of patient-derived fibroblasts and autopsied brain tissue; Sanger sequencing; genetic mapping","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal protein-level validation in patient fibroblasts and postmortem brain, replicated across multiple patients and families in two independent 2011 papers","pmids":["21855841","22036171"],"is_preprint":false},{"year":2011,"finding":"POLR3A (RPC1) and POLR3B (RPC2), the two largest Pol III subunits, together form the catalytic/active center of RNA Polymerase III and are jointly responsible for its transcriptional activity, including synthesis of tRNAs and 5S rRNA.","method":"Genetic analysis combined with functional inference from known Pol III structural biology; compound heterozygous mutations in POLR3A and POLR3B both disrupt catalytic activity","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Strong — established by genetic epistasis/conservation analysis across two papers; direct in vitro catalytic reconstitution not described in these abstracts","pmids":["22036171","21855841"],"is_preprint":false},{"year":2016,"finding":"A POLR3A founder mutation causing aberrant splicing and partial deficiency of full-length transcript leads to an overall decrease in Pol III-transcribed tRNA levels and imbalance in regulatory ncRNAs (snRNAs and snoRNAs), with downstream complex effects on the Pol II transcriptome affecting general RNA metabolism regulation.","method":"Transcriptome-wide analysis (RNA-seq) of patient-derived cells; RT-PCR splicing analysis; tRNA quantification","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptome-wide profiling with orthogonal RT-PCR validation, single lab","pmids":["27506977"],"is_preprint":false},{"year":2017,"finding":"A deep-intronic POLR3A mutation (c.1909+22G>A) activates a cryptic splice site in a tissue- and developmental stage-specific manner, establishing that non-coding/intronic variants in POLR3A reduce functional transcript levels in a tissue-specific fashion.","method":"RT-PCR and RNA splicing analysis; exome and targeted sequencing of cohort; segregation analysis","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — splicing demonstrated by RT-PCR with functional consequence, single lab but large cohort","pmids":["28459997"],"is_preprint":false},{"year":2017,"finding":"Knock-in mice homozygous (KI/KI) or compound heterozygous (KI/KO) for the French Canadian founder Polr3a G672E mutation show no overt myelination defects and normal Pol III transcript levels in brain, demonstrating that this single mutation in mice is insufficient to recapitulate the human hypomyelinating phenotype.","method":"Knock-in mouse model; behavioral tests; Luxol Fast Blue myelin staining; myelin protein quantification; qRT-PCR of Pol III transcripts","journal":"Molecular brain","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model with multiple orthogonal phenotyping methods (behavioral, histological, biochemical)","pmids":["28407788"],"is_preprint":false},{"year":2019,"finding":"CRISPR-Cas9 introduction of the POLR3A c.2554A→G (p.M852V) mutation into human cell lines reduces Pol III transcriptional output, causes a global reduction in tRNA levels, and specifically down-regulates brain cytoplasmic BC200 RNA (BCYRN1); in POLR3A-mutant oligodendroglial cells, MBP mRNA levels are significantly decreased upon differentiation. Genomic BC200 deletion causes larger transcriptomic and proteomic changes than POLR3A mutation alone.","method":"CRISPR-Cas9 mutagenesis; transcriptomic profiling; RT-qPCR; proteomics; patient-derived fibroblasts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — CRISPR-engineered isogenic cell lines with multiple orthogonal methods (transcriptomics, proteomics, qPCR) and patient cell validation","pmids":["30898877"],"is_preprint":false},{"year":2018,"finding":"Repression of Pol III transcription in S. cerevisiae under stress conditions leads to ubiquitylation of the largest Pol III subunit C160 (the yeast homolog of POLR3A/RPC1) and its subsequent proteasomal degradation, downstream of Pol III dissociation from chromatin. Blocking proteasomal degradation of C160 does not prevent proper transcriptional repression.","method":"Western blotting for C160 protein levels; detection of ubiquitylated C160; proteasome inhibitor treatment; chromatin occupancy assays; respiratory/rapamycin growth conditions","journal":"Biochimica et biophysica acta. Gene regulatory mechanisms","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ubiquitylation detection, proteasome inhibition, chromatin occupancy) in yeast ortholog with clear functional context","pmids":["30342998"],"is_preprint":false},{"year":2020,"finding":"HLD7-associated nonsense POLR3A mutation R140X causes the mutant protein to localize primarily as aggregates in lysosomes (rather than the nucleus as for wild-type protein), decreases mTOR signaling around lysosomes, and impairs oligodendroglial cell differentiation and myelin marker protein expression. Ibuprofen, an mTOR activator, partially rescues differentiation defects in cells expressing the R140X mutant.","method":"Fluorescence microscopy/confocal imaging; lysosome co-localization assay; mTOR signaling assays; oligodendroglial differentiation assay; myelin marker protein expression; ibuprofen treatment","journal":"Neurology international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by confocal imaging linked to functional consequence (mTOR signaling, differentiation), single lab","pmids":["35076634"],"is_preprint":false},{"year":2020,"finding":"HLD-causing missense mutations in POLR3A that cluster in the pore domain (which provides nucleotide access to the Pol III active site) were engineered into the yeast Rpc160 homolog; single mutations had no growth or transcription phenotype, but combining the pore mutations with a G672E mutation created double mutants with phenotypes ranging from wild-type to lethal. In the slowest-growing temperature-sensitive double mutant, global tRNA synthesis and RPR1/SNR52 RNA synthesis were compromised, and affinity-purified mutant Pol III showed defects in both factor-independent and factor-dependent transcription in vitro.","method":"Yeast genetics (engineered Rpc160 mutations); growth assays; in vitro transcription with affinity-purified Pol III; tRNA synthesis assays; RPR1/SNR52 RNA synthesis assays","journal":"Gene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstituted transcription assay with purified mutant Pol III plus in vivo genetic analysis; multiple orthogonal methods; single lab","pmids":["33148458"],"is_preprint":false},{"year":2020,"finding":"A POLR3A c.1771-6C>G splicing mutation causes aberrant splicing; in patient fibroblasts, expression levels of Pol III target genes (HNRNPH2, ubiquitin B, lactotransferrin, HSP90AA1) are decreased and are rescued to normal levels by overexpression of wild-type POLR3A but not by the p.Val1241Met variant, demonstrating that Val1241Met is a loss-of-function mutation affecting Pol III transcriptional activity.","method":"qRT-PCR; POLR3A overexpression rescue experiment in patient fibroblasts; RT-PCR for aberrant splicing","journal":"Neurology. Genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — rescue experiment with wild-type vs mutant overexpression provides functional hierarchy; single lab","pmids":["33134517"],"is_preprint":false},{"year":2020,"finding":"In WRS patient fibroblasts, a frameshift POLR3A mutation (c.3772_3773delCT) causes decreased wild-type POLR3A mRNA and protein, increased expression of the mutant protein, and increased nuclear localization of the mutant protein. These changes are associated with increased number/area of nucleoli, elevated pP53 and pH2AX signaling, and premature cellular senescence.","method":"RT-qPCR; immunoblotting; confocal microscopy for localization; SA-β-galactosidase senescence assay; immunofluorescence for pP53 and pH2AX","journal":"Mechanisms of ageing and development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization and functional consequence assays in patient-derived cells, single lab with multiple orthogonal methods","pmids":["32976914"],"is_preprint":false},{"year":2023,"finding":"Macrophage-derived DNA stimulates translocation of POLR3A from the nucleus to the perinuclear region near STING in fibroblasts and HUVECs, activating the POLR3A/STING/type I interferon response, monocyte adhesion, MCP-1 expression, and collagen overproduction. IRF3 (activated downstream of this pathway) directly binds the MCP-1 promoter. Knockdown of POLR3A or STING abolishes this response.","method":"Immunofluorescence/confocal microscopy for POLR3A subcellular localization; siRNA knockdown of POLR3A and STING; ChIP for IRF3 binding to MCP-1 promoter; Western blotting; STING knockout mouse model; bleomycin SSc mouse model","journal":"Rheumatology (Oxford, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with functional consequence, ChIP, genetic knockdown and KO rescue; single lab","pmids":["35686918"],"is_preprint":false},{"year":2024,"finding":"Overexpression of wild-type POLR3A significantly enhances Pol III transcription of 5S rRNA and tRNA Leu-CAA; a p.Cys767Phe mutant POLR3A, despite being expressed at higher levels than wild-type, fails to enhance Pol III transcription and instead reduces expression of POLR3A targets (BC200, tRNA Leu-CAA) and MBP/18S rRNA, demonstrating that the mutation causes a dominant-negative or loss-of-function effect on Pol III transcriptional activity.","method":"Cell transfection overexpression assay; RT-qPCR of Pol III target transcripts (5S rRNA, tRNA Leu-CAA, BC200, MBP, 18S rRNA)","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional overexpression assay with wild-type vs mutant comparison, multiple target transcripts; single lab","pmids":["38561452"],"is_preprint":false},{"year":2024,"finding":"Overproduction of the N-terminal fragment of the largest Pol III subunit C160 (C160-NTF, yeast POLR3A homolog) suppresses the maf1Δ phenotype by decreasing tRNA transcription and Pol III occupancy on tRNA genes. C160-NTF alters interactions of C160 with C34 and C82 subunits of the C82-34-31 heterotrimer, suggesting that the N-terminal region of POLR3A mediates assembly of this Pol III subcomplex.","method":"Yeast genetics (overdose suppressor screen); ChIP for Pol III occupancy; tRNA synthesis assays (newly synthesized tRNA); co-immunoprecipitation of Pol III subunits (C160/C34/C82 interactions); HA-tag localization by microscopy","journal":"Gene","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic suppressor screen with mechanistic follow-up by ChIP, tRNA synthesis, and Co-IP for subunit interactions; multiple orthogonal methods","pmids":["39142551"],"is_preprint":false},{"year":2025,"finding":"In WRS iPSCs carrying POLR3A mutations, POLR3A is upregulated during reprogramming; enhanced expression of mutant POLR3A leads to nucleolus abnormalities and sequestration of telomerase RNA component (TERC) in the nucleoli, establishing a functional link between POLR3A dysfunction, nucleolar structure, and telomerase RNA metabolism.","method":"iPSC reprogramming; immunofluorescence for nucleolar morphology; FISH/imaging for TERC localization in nucleoli","journal":"Biogerontology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct localization and functional consequence shown in iPSC model; single lab, single paper","pmids":["41081995"],"is_preprint":false},{"year":2026,"finding":"In zebrafish, loss of polr3a causes hypoplasia of neural crest cell-derived craniofacial cartilage and bone, reduced tRNA transcription, and reduced ribosome biogenesis. At larval stages, increased cell death occurs in craniofacial cartilage. Single-cell RNA-seq reveals upregulation of tp53, but Tp53 inhibition alone does not rescue craniofacial defects, indicating that additional downstream factors are required.","method":"Zebrafish polr3a mutant (loss-of-function); skeletal staining; cell death assays; tRNA transcription assays; ribosome biogenesis assays; single-cell RNA-seq; Tp53 inhibitor treatment","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods in loss-of-function vertebrate model (zebrafish KO), published as peer-reviewed full study","pmids":["42258504"],"is_preprint":false},{"year":2026,"finding":"Monoallelic (heterozygous) missense POLR3A variants cause impaired Pol III activity in patient-derived cells, including mis-regulation of individual Pol III targets and global downregulation of tRNA pools, without changes in POLR3A expression, subcellular localization, or subunit interactions. The neuropathy-associated variants cluster in regions critical for Pol III catalytic activity and do not overlap with known biallelic disease-causing variants.","method":"Patient-derived cell transcriptomics; tRNA pool quantification; immunoblotting; subcellular fractionation; interactomics (subunit interaction assays); structural modelling","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (transcriptomics, interactomics, localization, structural modelling) in patient-derived cells; peer-reviewed publication","pmids":["42260910"],"is_preprint":false},{"year":2026,"finding":"CRISPR-dCas13Rx targeting of POLR3A exon regions harboring disease-causing missense mutations reveals that ~20% of interrogated exon regions affect RNA splicing; minigene assays confirm that specific mutations (in exons 14 and 26) cause splicing aberrations. Antisense oligonucleotides (ASOs) targeting intronic elements identified by this approach rescue correct splicing of POLR3A in EcR293 and oligodendroglioma cell lines.","method":"CRISPR-dCas13Rx splicing interference; minigene splicing assays; antisense oligonucleotide (ASO) treatment; RT-PCR splicing analysis","journal":"Molecular therapy. Nucleic acids","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal functional assays (CRISPR-dCas13Rx, minigene, ASO rescue) establishing splicing mechanism; single lab","pmids":["41732205"],"is_preprint":false},{"year":2024,"finding":"Progesterone receptor (PR) co-occupies ~50% of POLR3A-occupied tRNA genes upon progestin treatment, co-recruiting Maf1 to these sites. Maf1 knockdown significantly reduces progestin-induced tRNA transcription repression, establishing that PR-mediated repression of select tRNA genes by POLR3A requires Maf1 as a necessary effector.","method":"ChIP-seq for POLR3A, PR, Brf1 (TFIIIB), and Maf1; nascent tRNA transcription assays; Maf1 siRNA knockdown","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq with functional knockdown validation; preprint, single lab","pmids":[],"is_preprint":true}],"current_model":"POLR3A (RPC1/RPC155) encodes the largest catalytic subunit of RNA Polymerase III, forming the active center together with POLR3B; it is required for transcription of tRNAs, 5S rRNA, BC200 RNA, and other small non-coding RNAs essential for translation and cellular homeostasis. Disease-causing mutations reduce Pol III transcriptional output (globally decreasing tRNA pools and specific ncRNAs such as BC200), with some mutations causing aberrant splicing, lysosomal mislocalization with mTOR pathway disruption, or premature senescence with nucleolar abnormalities. Under stress, the yeast ortholog (C160) is ubiquitylated and degraded by the proteasome downstream of chromatin dissociation. The N-terminal domain of C160/POLR3A mediates assembly with the C82-34-31 heterotrimer. In the innate immune context, cytoplasmic DNA triggers perinuclear POLR3A relocalization to activate the STING/IRF3/type I interferon axis. In vivo, Polr3a loss in zebrafish reduces tRNA transcription and ribosome biogenesis, causing neural crest-derived craniofacial defects partly through tp53 upregulation."},"narrative":{"mechanistic_narrative":"POLR3A (RPC1/RPC155) encodes the largest catalytic subunit of RNA Polymerase III, which together with POLR3B forms the enzyme's active center responsible for transcribing tRNAs, 5S rRNA, BC200 (BCYRN1), and other small non-coding RNAs essential for translation and cellular homeostasis [PMID:22036171, PMID:21855841, PMID:30898877]. Its N-terminal region mediates assembly of the polymerase by engaging the C82-34-31 heterotrimer, and disease-clustered residues in the pore domain control nucleotide access to the catalytic site [PMID:39142551, PMID:33148458]. Recessive, monoallelic, and splice-altering POLR3A mutations converge on reduced Pol III output, depleting global tRNA pools and specific transcripts such as BC200, which impairs oligodendroglial differentiation and myelin marker expression; this links POLR3A to hypomyelinating leukodystrophy and to a distinct neuropathy caused by catalytic-region monoallelic variants [PMID:30898877, PMID:42260910, PMID:21855841, PMID:22036171]. Beyond loss of catalytic output, individual mutations produce protein-level pathologies: a nonsense allele mislocalizes POLR3A to lysosomes and lowers peri-lysosomal mTOR signaling [PMID:35076634], while frameshift mutations associated with Wiedemann-Rautenstrauch syndrome drive nuclear accumulation of mutant protein, nucleolar abnormalities with TERC sequestration, elevated p53/H2AX signaling, and premature senescence [PMID:32976914, PMID:41081995]. POLR3A also functions outside canonical transcription as a cytosolic DNA sensor: cytoplasmic DNA triggers its relocalization to perinuclear sites near STING, activating an IRF3-dependent type I interferon and pro-fibrotic response [PMID:35686918]. In vivo, polr3a loss in zebrafish reduces tRNA transcription and ribosome biogenesis, causing tp53-associated neural crest craniofacial defects [PMID:42258504].","teleology":[{"year":2011,"claim":"Established that POLR3A is the largest catalytic subunit of Pol III and that its mutation reduces protein levels to impair CNS myelination, defining the gene as essential for the leukodystrophy phenotype.","evidence":"Immunoblotting of patient fibroblasts and autopsied brain; genetic mapping and Sanger sequencing across families","pmids":["21855841","22036171"],"confidence":"High","gaps":["Did not establish the molecular mechanism linking reduced Pol III output to myelination","Catalytic activity inferred from structure rather than reconstituted"]},{"year":2011,"claim":"Defined POLR3A and POLR3B as jointly forming the Pol III active center, anchoring the enzyme's transcriptional activity.","evidence":"Genetic analysis of compound heterozygous mutations combined with structural inference","pmids":["22036171","21855841"],"confidence":"Medium","gaps":["No direct in vitro catalytic reconstitution in these reports","Subunit contributions to individual transcript classes not resolved"]},{"year":2016,"claim":"Showed that a splicing-deficient POLR3A founder allele reduces full-length transcript and depletes tRNAs and regulatory ncRNAs, extending impact to the Pol II transcriptome.","evidence":"RNA-seq of patient cells with RT-PCR splicing analysis and tRNA quantification","pmids":["27506977"],"confidence":"Medium","gaps":["Single lab","Causal chain from ncRNA imbalance to disease not established"]},{"year":2017,"claim":"Demonstrated that intronic POLR3A variants reduce functional transcript in a tissue- and stage-specific manner, broadening the mutational spectrum beyond coding changes.","evidence":"RT-PCR splicing analysis and cohort exome/targeted sequencing with segregation","pmids":["28459997"],"confidence":"Medium","gaps":["Tissue-specificity mechanism unresolved","Quantitative threshold for disease not defined"]},{"year":2017,"claim":"Tested whether a single founder mutation suffices for disease in vivo; the knock-in mouse failed to recapitulate hypomyelination, revealing species- or allele-specific dependence.","evidence":"Polr3a G672E knock-in mouse with behavioral, histological, and biochemical phenotyping","pmids":["28407788"],"confidence":"High","gaps":["Does not explain why human carriers develop disease","Compound allele combinations not modeled"]},{"year":2019,"claim":"Provided isogenic causal evidence that a POLR3A point mutation reduces Pol III output, depletes tRNAs and BC200, and lowers MBP upon oligodendroglial differentiation.","evidence":"CRISPR-engineered cell lines with transcriptomics, proteomics, qPCR, and patient cell validation","pmids":["30898877"],"confidence":"High","gaps":["Relative contribution of each depleted ncRNA to myelination unresolved","Did not address dominant vs recessive mechanism"]},{"year":2018,"claim":"Identified post-transcriptional regulation of the largest subunit: under stress its yeast ortholog is ubiquitylated and proteasomally degraded after chromatin dissociation, separate from the repression event itself.","evidence":"Yeast Western blotting, ubiquitylation detection, proteasome inhibition, and chromatin occupancy assays","pmids":["30342998"],"confidence":"High","gaps":["E3 ligase not identified","Conservation of this turnover in human POLR3A untested"]},{"year":2020,"claim":"Mapped disease mutations to the pore domain and showed via reconstituted transcription that combinations of mutations compromise both factor-independent and factor-dependent Pol III activity.","evidence":"Engineered yeast Rpc160 mutants, growth assays, and in vitro transcription with affinity-purified Pol III","pmids":["33148458"],"confidence":"High","gaps":["Single mutations were phenotypically silent in yeast","Direct translation to human catalytic defect inferred"]},{"year":2020,"claim":"Established a loss-of-function hierarchy by rescue, showing wild-type but not the p.Val1241Met POLR3A restores Pol III target gene expression.","evidence":"qRT-PCR and overexpression rescue in patient fibroblasts with RT-PCR splicing analysis","pmids":["33134517"],"confidence":"Medium","gaps":["Single lab","Target genes assayed are a limited panel"]},{"year":2020,"claim":"Revealed a protein-mislocalization mechanism: a nonsense allele aggregates in lysosomes, lowers peri-lysosomal mTOR signaling, and impairs differentiation, with partial mTOR-activator rescue.","evidence":"Confocal lysosome co-localization, mTOR signaling assays, oligodendroglial differentiation, and ibuprofen treatment","pmids":["35076634"],"confidence":"Medium","gaps":["Mechanism of lysosomal targeting unknown","mTOR link based on a single mutant"]},{"year":2020,"claim":"Connected POLR3A frameshift mutation to a senescence pathology, with nuclear accumulation of mutant protein, nucleolar expansion, and elevated p53/H2AX signaling.","evidence":"RT-qPCR, immunoblotting, confocal localization, SA-β-gal, and pP53/pH2AX immunofluorescence in WRS fibroblasts","pmids":["32976914"],"confidence":"Medium","gaps":["Causal link from nucleolar change to senescence not dissected","Single lab"]},{"year":2023,"claim":"Uncovered a non-transcriptional role: cytoplasmic DNA drives POLR3A perinuclear relocalization to STING, activating IRF3-dependent interferon and pro-fibrotic responses.","evidence":"Confocal localization, siRNA knockdown, IRF3 ChIP on the MCP-1 promoter, and STING-knockout/bleomycin mouse models","pmids":["35686918"],"confidence":"Medium","gaps":["Mechanism of DNA recognition by POLR3A unresolved","Single lab"]},{"year":2024,"claim":"Demonstrated that a missense mutant fails to enhance Pol III transcription despite higher expression, indicating a dominant-negative/loss-of-function effect on multiple targets.","evidence":"Overexpression transfection with RT-qPCR of 5S rRNA, tRNA Leu-CAA, BC200, MBP, and 18S rRNA","pmids":["38561452"],"confidence":"Medium","gaps":["Dominant-negative versus loss-of-function not formally distinguished","Single lab"]},{"year":2024,"claim":"Defined the N-terminal region of the largest subunit as the assembly module that binds the C82-34-31 heterotrimer, linking its overproduction to altered tRNA gene occupancy.","evidence":"Yeast overdose suppressor screen, ChIP for Pol III occupancy, tRNA synthesis assays, and Co-IP of C160/C34/C82","pmids":["39142551"],"confidence":"High","gaps":["Structural basis of the N-terminal interaction not solved","Human POLR3A assembly inferred from yeast"]},{"year":2024,"claim":"Placed POLR3A within hormonal control of tRNA genes, showing PR co-occupancy and Maf1 co-recruitment are required for progestin-induced tRNA repression.","evidence":"ChIP-seq for POLR3A/PR/Brf1/Maf1 with nascent tRNA assays and Maf1 knockdown (preprint)","pmids":[],"confidence":"Medium","gaps":["Preprint, single lab","Direct PR-POLR3A contact not demonstrated"]},{"year":2025,"claim":"Linked POLR3A dysfunction to telomerase RNA metabolism, showing mutant protein causes nucleolar abnormalities and sequesters TERC in nucleoli.","evidence":"WRS iPSC reprogramming with nucleolar immunofluorescence and TERC FISH imaging","pmids":["41081995"],"confidence":"Medium","gaps":["Functional consequence of TERC sequestration for telomerase activity untested","Single lab"]},{"year":2026,"claim":"Defined a distinct monoallelic neuropathy mechanism: catalytic-region variants impair Pol III activity and deplete tRNAs without altering POLR3A expression, localization, or subunit interactions.","evidence":"Patient-cell transcriptomics, tRNA quantification, fractionation, interactomics, and structural modelling","pmids":["42260910"],"confidence":"High","gaps":["How catalytic depletion produces peripheral rather than central pathology unresolved","Specific affected tRNA isoacceptors not fully mapped"]},{"year":2026,"claim":"Established polr3a loss in a vertebrate causes neural-crest craniofacial defects via reduced tRNA transcription and ribosome biogenesis, with tp53 upregulation insufficient to explain the phenotype.","evidence":"Zebrafish loss-of-function mutant with skeletal staining, cell death and ribosome assays, scRNA-seq, and Tp53 inhibition","pmids":["42258504"],"confidence":"High","gaps":["Additional downstream effectors beyond tp53 unidentified","Cell-type specificity of vulnerability unresolved"]},{"year":2026,"claim":"Demonstrated a therapeutic splicing-correction strategy, identifying mutation-induced splicing aberrations and rescuing them with antisense oligonucleotides.","evidence":"CRISPR-dCas13Rx splicing interference, minigene assays, and ASO rescue with RT-PCR","pmids":["41732205"],"confidence":"High","gaps":["In vivo efficacy not demonstrated","Fraction of disease alleles amenable to ASO correction unknown"]},{"year":null,"claim":"How distinct POLR3A mutations produce divergent tissue phenotypes (hypomyelination, neuropathy, progeroid senescence, craniofacial defects) from a shared reduction in Pol III output remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking specific tRNA/ncRNA deficits to specific tissue vulnerabilities","Genotype-phenotype rules for coding vs splice vs mislocalizing alleles undefined","Mechanism of the non-canonical DNA-sensing role versus the transcriptional role not integrated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[1,5,8,16]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[11]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,8,18]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[7,10,11]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[10,14]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,5,8]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[2,5,15]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[15]}],"complexes":["RNA Polymerase III"],"partners":["POLR3B","POLR3F","POLR3H","POLR3G","MAF1","STING1","PGR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O14802","full_name":"DNA-directed RNA polymerase III subunit RPC1","aliases":["DNA-directed RNA polymerase III largest subunit","DNA-directed RNA polymerase III subunit A","RNA polymerase III 155 kDa subunit","RPC155","RNA polymerase III subunit C160"],"length_aa":1390,"mass_kda":155.6,"function":"Catalytic core component of RNA polymerase III (Pol III), a DNA-dependent RNA polymerase which synthesizes small non-coding RNAs using the four ribonucleoside triphosphates as substrates. Synthesizes 5S rRNA, snRNAs, tRNAs and miRNAs from at least 500 distinct genomic loci (PubMed:19609254, PubMed:19631370, PubMed:20413673, PubMed:33335104, PubMed:33558764, PubMed:33558766, PubMed:34675218, PubMed:35637192, PubMed:9331371). Pol III-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol III is recruited to DNA promoters type I, II or III with the help of general transcription factors and other specific initiation factors. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (PubMed:20413673, PubMed:33335104, PubMed:33558764, PubMed:33558766, PubMed:33674783, PubMed:34675218). Forms Pol III active center together with the second largest subunit POLR3B/RPC2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR3A/RPC1 contributing a Mg(2+)-coordinating DxDGD motif, and POLR3B/RPC2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate (PubMed:19609254, PubMed:20413673, PubMed:33335104, PubMed:33558764, PubMed:33674783, PubMed:34675218, PubMed:9331371). Pol III plays a key role in sensing and limiting infection by intracellular bacteria and DNA viruses. Acts as a nuclear and cytosolic DNA sensor involved in innate immune response. Can sense non-self dsDNA that serves as template for transcription into dsRNA. The non-self RNA polymerase III transcripts, such as Epstein-Barr virus-encoded RNAs (EBERs) induce type I interferon and NF-kappa-B through the RIG-I pathway","subcellular_location":"Nucleus; Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/O14802/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/POLR3A","classification":"Common Essential","n_dependent_lines":1207,"n_total_lines":1208,"dependency_fraction":0.9991721854304636},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000148606","cell_line_id":"CID000709","localizations":[{"compartment":"nuclear_punctae","grade":3},{"compartment":"nucleoplasm","grade":2}],"interactors":[{"gene":"POLR1C","stoichiometry":10.0},{"gene":"POLR1D","stoichiometry":10.0},{"gene":"POLR2E","stoichiometry":10.0},{"gene":"POLR2F","stoichiometry":10.0},{"gene":"POLR2H","stoichiometry":10.0},{"gene":"POLR2K","stoichiometry":10.0},{"gene":"CRCP","stoichiometry":10.0},{"gene":"POLR3D","stoichiometry":10.0},{"gene":"POLR3G","stoichiometry":10.0},{"gene":"POLR3C","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/target/CID000709","total_profiled":1310},"omim":[{"mim_id":"617454","title":"POLYMERASE III, RNA, SUBUNIT C; POLR3C","url":"https://www.omim.org/entry/617454"},{"mim_id":"616513","title":"La RIBONUCLEOPROTEIN 4B; LARP4B","url":"https://www.omim.org/entry/616513"},{"mim_id":"616494","title":"LEUKODYSTROPHY, HYPOMYELINATING, 11; HLD11","url":"https://www.omim.org/entry/616494"},{"mim_id":"614381","title":"LEUKODYSTROPHY, HYPOMYELINATING, 8, WITH OR WITHOUT OLIGODONTIA AND/OR HYPOGONADOTROPIC HYPOGONADISM; HLD8","url":"https://www.omim.org/entry/614381"},{"mim_id":"614366","title":"POLYMERASE III, RNA, SUBUNIT B; POLR3B","url":"https://www.omim.org/entry/614366"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/POLR3A"},"hgnc":{"alias_symbol":["RPC1","RPC155","hRPC155","C160"],"prev_symbol":[]},"alphafold":{"accession":"O14802","domains":[{"cath_id":"-","chopping":"22-84_259-268","consensus_level":"medium","plddt":88.5027,"start":22,"end":268},{"cath_id":"-","chopping":"96-175_219-247","consensus_level":"high","plddt":90.3661,"start":96,"end":247},{"cath_id":"-","chopping":"180-215","consensus_level":"medium","plddt":74.0125,"start":180,"end":215},{"cath_id":"-","chopping":"278-346","consensus_level":"medium","plddt":90.0522,"start":278,"end":346},{"cath_id":"2.40.40.20","chopping":"365-528","consensus_level":"medium","plddt":93.6637,"start":365,"end":528},{"cath_id":"1.10.274.100","chopping":"544-683","consensus_level":"high","plddt":91.7748,"start":544,"end":683},{"cath_id":"1.10.132.30","chopping":"701-841","consensus_level":"high","plddt":88.9048,"start":701,"end":841},{"cath_id":"-","chopping":"909-1030","consensus_level":"medium","plddt":88.3167,"start":909,"end":1030}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14802","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14802-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14802-F1-predicted_aligned_error_v6.png","plddt_mean":88.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=POLR3A","jax_strain_url":"https://www.jax.org/strain/search?query=POLR3A"},"sequence":{"accession":"O14802","fasta_url":"https://rest.uniprot.org/uniprotkb/O14802.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14802/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14802"}},"corpus_meta":[{"pmid":"21855841","id":"PMC_21855841","title":"Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy.","date":"2011","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21855841","citation_count":221,"is_preprint":false},{"pmid":"25339210","id":"PMC_25339210","title":"Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations.","date":"2014","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25339210","citation_count":173,"is_preprint":false},{"pmid":"22036171","id":"PMC_22036171","title":"Mutations in POLR3A and POLR3B encoding RNA Polymerase III subunits cause an autosomal-recessive hypomyelinating leukoencephalopathy.","date":"2011","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22036171","citation_count":137,"is_preprint":false},{"pmid":"28459997","id":"PMC_28459997","title":"Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive spastic ataxia.","date":"2017","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28459997","citation_count":99,"is_preprint":false},{"pmid":"23355746","id":"PMC_23355746","title":"Mutations in POLR3A and POLR3B are a major cause of hypomyelinating leukodystrophies with or without dental abnormalities and/or hypogonadotropic hypogonadism.","date":"2013","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23355746","citation_count":92,"is_preprint":false},{"pmid":"27506977","id":"PMC_27506977","title":"Transcriptome-wide effects of a POLR3A gene mutation in patients with an unusual phenotype of striatal involvement.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27506977","citation_count":58,"is_preprint":false},{"pmid":"22451160","id":"PMC_22451160","title":"4H syndrome with late-onset growth hormone deficiency caused by POLR3A mutations.","date":"2012","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/22451160","citation_count":49,"is_preprint":false},{"pmid":"30414627","id":"PMC_30414627","title":"Bi-allelic POLR3A Loss-of-Function Variants Cause Autosomal-Recessive Wiedemann-Rautenstrauch Syndrome.","date":"2018","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30414627","citation_count":47,"is_preprint":false},{"pmid":"30898877","id":"PMC_30898877","title":"Leukodystrophy-associated POLR3A mutations down-regulate the RNA polymerase III transcript and important regulatory RNA BC200.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30898877","citation_count":47,"is_preprint":false},{"pmid":"30323018","id":"PMC_30323018","title":"Specific combinations of biallelic POLR3A variants cause Wiedemann-Rautenstrauch syndrome.","date":"2018","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30323018","citation_count":46,"is_preprint":false},{"pmid":"27612211","id":"PMC_27612211","title":"Neonatal progeriod syndrome associated with biallelic truncating variants in POLR3A.","date":"2016","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/27612211","citation_count":35,"is_preprint":false},{"pmid":"28407788","id":"PMC_28407788","title":"Absence of neurological abnormalities in mice homozygous for the Polr3a G672E hypomyelinating leukodystrophy mutation.","date":"2017","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/28407788","citation_count":33,"is_preprint":false},{"pmid":"31932101","id":"PMC_31932101","title":"POLR3A variants in striatal involvement without diffuse hypomyelination.","date":"2020","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/31932101","citation_count":26,"is_preprint":false},{"pmid":"31438894","id":"PMC_31438894","title":"Novel mutations of the POLR3A gene caused POLR3-related leukodystrophy in a Chinese family: a case report.","date":"2019","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/31438894","citation_count":25,"is_preprint":false},{"pmid":"23643445","id":"PMC_23643445","title":"Different patterns of cerebellar abnormality and hypomyelination between POLR3A and POLR3B mutations.","date":"2013","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/23643445","citation_count":23,"is_preprint":false},{"pmid":"31637490","id":"PMC_31637490","title":"POLR3A-related spastic ataxia: new mutations and a look into the phenotype.","date":"2019","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31637490","citation_count":22,"is_preprint":false},{"pmid":"32982993","id":"PMC_32982993","title":"GnRH Deficient Patients With Congenital Hypogonadotropic Hypogonadism: Novel Genetic Findings in ANOS1, RNF216, WDR11, FGFR1, CHD7, and POLR3A Genes in a Case Series and Review of the Literature.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32982993","citation_count":22,"is_preprint":false},{"pmid":"23694757","id":"PMC_23694757","title":"Novel compound heterozygous mutations of POLR3A revealed by whole-exome sequencing in a patient with hypomyelination.","date":"2013","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/23694757","citation_count":21,"is_preprint":false},{"pmid":"30450527","id":"PMC_30450527","title":"Analyses of LMNA-negative juvenile progeroid cases confirms biallelic POLR3A mutations in Wiedemann-Rautenstrauch-like syndrome and expands the phenotypic spectrum of PYCR1 mutations.","date":"2018","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30450527","citation_count":21,"is_preprint":false},{"pmid":"34296356","id":"PMC_34296356","title":"POLR3A variants in hereditary spastic paraparesis and ataxia: clinical, genetic, and neuroradiological findings in a cohort of Italian patients.","date":"2021","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/34296356","citation_count":19,"is_preprint":false},{"pmid":"26096995","id":"PMC_26096995","title":"Exome sequencing reveals a novel WDR45 frameshift mutation and inherited POLR3A heterozygous variants in a female with a complex phenotype and mixed brain MRI findings.","date":"2015","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26096995","citation_count":19,"is_preprint":false},{"pmid":"29618326","id":"PMC_29618326","title":"A novel homozygous mutation in POLR3A gene causing 4H syndrome: a case report.","date":"2018","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/29618326","citation_count":17,"is_preprint":false},{"pmid":"32976914","id":"PMC_32976914","title":"Nucleolar disruption, activation of P53 and premature senescence in POLR3A-mutated Wiedemann-Rautenstrauch syndrome fibroblasts.","date":"2020","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/32976914","citation_count":16,"is_preprint":false},{"pmid":"36140376","id":"PMC_36140376","title":"Identification of a Novel Missense Mutation of POLR3A Gene in a Cohort of Sicilian Patients with Leukodystrophy.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36140376","citation_count":15,"is_preprint":false},{"pmid":"26011300","id":"PMC_26011300","title":"POLR3A and POLR3B Mutations in Unclassified Hypomyelination.","date":"2015","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/26011300","citation_count":15,"is_preprint":false},{"pmid":"32555393","id":"PMC_32555393","title":"Unique combination and in silico modeling of biallelic POLR3A variants as a cause of Wiedemann-Rautenstrauch syndrome.","date":"2020","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/32555393","citation_count":12,"is_preprint":false},{"pmid":"35686918","id":"PMC_35686918","title":"DNA from macrophages induces fibrosis and vasculopathy through POLR3A/STING/type I interferon axis in systemic sclerosis.","date":"2023","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35686918","citation_count":11,"is_preprint":false},{"pmid":"35076634","id":"PMC_35076634","title":"Hypomyelinating Leukodystrophy 7 (HLD7)-Associated Mutation of POLR3A Is Related to Defective Oligodendroglial Cell Differentiation, Which Is Ameliorated by Ibuprofen.","date":"2021","source":"Neurology international","url":"https://pubmed.ncbi.nlm.nih.gov/35076634","citation_count":11,"is_preprint":false},{"pmid":"32600288","id":"PMC_32600288","title":"A novel POLR3A genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onset.","date":"2020","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32600288","citation_count":11,"is_preprint":false},{"pmid":"30342998","id":"PMC_30342998","title":"Repression of yeast RNA polymerase III by stress leads to ubiquitylation and proteasomal degradation of its largest subunit, C160.","date":"2018","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/30342998","citation_count":10,"is_preprint":false},{"pmid":"31306222","id":"PMC_31306222","title":"A 42-year-old woman with 4H leukodystrophy caused by a homozygous mutation in POLR3A gene.","date":"2019","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/31306222","citation_count":10,"is_preprint":false},{"pmid":"37197783","id":"PMC_37197783","title":"Craniofacial features of POLR3-related leukodystrophy caused by biallelic variants in POLR3A, POLR3B and POLR1C.","date":"2023","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37197783","citation_count":9,"is_preprint":false},{"pmid":"32597037","id":"PMC_32597037","title":"Interpretation challenges of novel dual-class missense and splice-impacting variant in POLR3A-related late-onset hereditary spastic ataxia.","date":"2020","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32597037","citation_count":9,"is_preprint":false},{"pmid":"33148458","id":"PMC_33148458","title":"Functional characterization of Polr3a hypomyelinating leukodystrophy mutations in the S. cerevisiae homolog, RPC160.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/33148458","citation_count":8,"is_preprint":false},{"pmid":"33134517","id":"PMC_33134517","title":"Neurodevelopmental regression, severe generalized dystonia, and metabolic acidosis caused by POLR3A mutations.","date":"2020","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33134517","citation_count":8,"is_preprint":false},{"pmid":"38561452","id":"PMC_38561452","title":"Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38561452","citation_count":6,"is_preprint":false},{"pmid":"36397839","id":"PMC_36397839","title":"Developmental regression and movement disorder as a phenotypic variant of POLR3A Mutation-Case report.","date":"2022","source":"Clinical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/36397839","citation_count":6,"is_preprint":false},{"pmid":"35730126","id":"PMC_35730126","title":"Circ-POLR3A accelerates TGF-β2-induced promotion in cell viability, migration, and invasion of lens epithelial cells via miR-31/TXNIP signaling cascade.","date":"2022","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/35730126","citation_count":5,"is_preprint":false},{"pmid":"36988728","id":"PMC_36988728","title":"A novel variant of the POLR3A gene in a Chinese patient with POLR3-related leukodystrophy.","date":"2023","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/36988728","citation_count":5,"is_preprint":false},{"pmid":"34753215","id":"PMC_34753215","title":"Spinal cord-predominant neuropathology in an adult-onset case of POLR3A-related spastic ataxia.","date":"2021","source":"Neuropathology : official journal of the Japanese Society of Neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/34753215","citation_count":5,"is_preprint":false},{"pmid":"33085208","id":"PMC_33085208","title":"Multimodal evaluation of an Italian family with a hereditary spastic paraplegia and POLR3A mutations.","date":"2020","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33085208","citation_count":5,"is_preprint":false},{"pmid":"38550343","id":"PMC_38550343","title":"POLR3-related leukodystrophy caused by biallelic POLR3A and 1C pathogenic variants: a single-center experience.","date":"2024","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38550343","citation_count":4,"is_preprint":false},{"pmid":"37965164","id":"PMC_37965164","title":"A Chinese patient with POLR3A-related leukodystrophy: a case report and literature review.","date":"2023","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37965164","citation_count":4,"is_preprint":false},{"pmid":"27852030","id":"PMC_27852030","title":"[A Case of Pol III-related Leukodystrophy with Homozygous Mutation in POLR3A].","date":"2016","source":"Brain and nerve = Shinkei kenkyu no shinpo","url":"https://pubmed.ncbi.nlm.nih.gov/27852030","citation_count":4,"is_preprint":false},{"pmid":"38348603","id":"PMC_38348603","title":"Further delineation of Wiedemann-Rautenstrauch syndrome linked with POLR3A.","date":"2024","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38348603","citation_count":3,"is_preprint":false},{"pmid":"18943106","id":"PMC_18943106","title":"Molecular mapping of the crown rust resistance gene rpc1 in barley.","date":"2004","source":"Phytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/18943106","citation_count":3,"is_preprint":false},{"pmid":"35691411","id":"PMC_35691411","title":"A novel variant of the POLR3A gene in a patient with hypomyelinating POLR3-related leukodystrophy.","date":"2022","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35691411","citation_count":3,"is_preprint":false},{"pmid":"33491183","id":"PMC_33491183","title":"Two intronic cis-acting variants in both alleles of the POLR3A gene cause progressive spastic ataxia with hypodontia.","date":"2021","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33491183","citation_count":3,"is_preprint":false},{"pmid":"23965854","id":"PMC_23965854","title":"[A case of hypomyelinating leukodystrophy with new homozygous mutation in POLR3A].","date":"2013","source":"Rinsho shinkeigaku = Clinical neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23965854","citation_count":3,"is_preprint":false},{"pmid":"38852424","id":"PMC_38852424","title":"Production of an induced pluripotent stem cell line CSSi018-A (14192) from a patient with hypomyelinating leukodystrophy 7 (HLD7) carrying biallelic variants of POLR3A (c.1802 T > A; c.4072G > A).","date":"2024","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38852424","citation_count":2,"is_preprint":false},{"pmid":"41732205","id":"PMC_41732205","title":"RNA-based discovery and correction of splicing defects caused by POLR3A missense mutations.","date":"2026","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/41732205","citation_count":1,"is_preprint":false},{"pmid":"40518520","id":"PMC_40518520","title":"POLR3A rare variants in a patient with intellectual disability, ataxic gait and cortical malformations: a case-report.","date":"2025","source":"Italian journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/40518520","citation_count":1,"is_preprint":false},{"pmid":"39436788","id":"PMC_39436788","title":"Tremor Ataxia With Central Hypomyelation Phenotype Related to a Recurrent POLR3A Mutation in Six Unrelated Tunisian Families.","date":"2024","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39436788","citation_count":1,"is_preprint":false},{"pmid":"38437768","id":"PMC_38437768","title":"An iPSC model for POLR3A-associated spastic ataxia: Generation of three unrelated patient cell lines.","date":"2024","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38437768","citation_count":1,"is_preprint":false},{"pmid":"41081995","id":"PMC_41081995","title":"POLR3A mutations cause nucleolus abnormalities and aberrant telomerase RNA metabolism in induced pluripotent stem cells from Wiedemann-Rautenstrauch premature aging syndrome patient.","date":"2025","source":"Biogerontology","url":"https://pubmed.ncbi.nlm.nih.gov/41081995","citation_count":0,"is_preprint":false},{"pmid":"39142551","id":"PMC_39142551","title":"Functional suppression of a yeast maf1 deletion mutant by overdose of the N-terminal fragment of the largest RNA polymerase III subunit, C160.","date":"2024","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/39142551","citation_count":0,"is_preprint":false},{"pmid":"41542503","id":"PMC_41542503","title":"RNA Polymerase III subunit Polr3a is required for craniofacial cartilage and bone development.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41542503","citation_count":0,"is_preprint":false},{"pmid":"41634725","id":"PMC_41634725","title":"Study of POLR3A variants in a family trio suggests mutation-specific pathogenetic mechanisms: insights from integrative OMIC approaches.","date":"2026","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/41634725","citation_count":0,"is_preprint":false},{"pmid":"42258504","id":"PMC_42258504","title":"RNA Polymerase III subunit Polr3a is required for craniofacial cartilage and bone development in zebrafish.","date":"2026","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/42258504","citation_count":0,"is_preprint":false},{"pmid":"41549341","id":"PMC_41549341","title":"Novel POLR3A Gene Mutation Results in Wiedemann-Rautenstrauch Syndrome With Striking Cutis Laxa and Myelofibrosis.","date":"2026","source":"The Journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/41549341","citation_count":0,"is_preprint":false},{"pmid":"42260910","id":"PMC_42260910","title":"Monoallelic POLR3A Variants Cause Early-Onset Peripheral Neuropathy.","date":"2026","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/42260910","citation_count":0,"is_preprint":false},{"pmid":"41716259","id":"PMC_41716259","title":"POLR3A-related syndrome complicated with cerebral abscesses: a case report and literature review.","date":"2026","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41716259","citation_count":0,"is_preprint":false},{"pmid":"40912518","id":"PMC_40912518","title":"Clinical and molecular insights into Wiedemann-Rautenstrauch syndrome: A case report and genetic analysis of the c.2707G>A variant in the POLR3A gene.","date":"2025","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/40912518","citation_count":0,"is_preprint":false},{"pmid":"42113100","id":"PMC_42113100","title":"Expanding the genetic spectrum of neurogenetic disorders in moroccan families by exome sequencing: identification of candidate variants in RYR3, POLR3A, and LAMA2.","date":"2026","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/42113100","citation_count":0,"is_preprint":false},{"pmid":"40917817","id":"PMC_40917817","title":"\"Deep Brain Stimulation of the Ventral Intermediate Nucleus of the Thalamus for Tremor in Polr3a-Related Tremor-ataxia Syndrome: A Two-case Report\".","date":"2025","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/40917817","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.16.25331559","title":"Monoallelic <i>POLR3A</i> variants cause a Pol III-related disorder characterized by peripheral neuropathy","date":"2025-07-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.16.25331559","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.16.628719","title":"Maf1 Cooperates with Progesterone Receptor to Repress RNA Polymerase III Transcription of Select tRNAs","date":"2024-12-16","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.16.628719","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":35081,"output_tokens":5316,"usd":0.092492,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13688,"output_tokens":5404,"usd":0.10177,"stage2_stop_reason":"end_turn"},"total_usd":0.194262,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"POLR3A encodes the largest (RPC1/RPC155) catalytic subunit of RNA Polymerase III; recessive missense and insertion mutations in POLR3A cause a significant decrease in POLR3A protein levels in patient fibroblasts and brain tissue, with greater reduction in cerebral white matter than cortex, establishing POLR3A as essential for CNS myelination.\",\n      \"method\": \"Immunoblotting of patient-derived fibroblasts and autopsied brain tissue; Sanger sequencing; genetic mapping\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal protein-level validation in patient fibroblasts and postmortem brain, replicated across multiple patients and families in two independent 2011 papers\",\n      \"pmids\": [\"21855841\", \"22036171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"POLR3A (RPC1) and POLR3B (RPC2), the two largest Pol III subunits, together form the catalytic/active center of RNA Polymerase III and are jointly responsible for its transcriptional activity, including synthesis of tRNAs and 5S rRNA.\",\n      \"method\": \"Genetic analysis combined with functional inference from known Pol III structural biology; compound heterozygous mutations in POLR3A and POLR3B both disrupt catalytic activity\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Strong — established by genetic epistasis/conservation analysis across two papers; direct in vitro catalytic reconstitution not described in these abstracts\",\n      \"pmids\": [\"22036171\", \"21855841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A POLR3A founder mutation causing aberrant splicing and partial deficiency of full-length transcript leads to an overall decrease in Pol III-transcribed tRNA levels and imbalance in regulatory ncRNAs (snRNAs and snoRNAs), with downstream complex effects on the Pol II transcriptome affecting general RNA metabolism regulation.\",\n      \"method\": \"Transcriptome-wide analysis (RNA-seq) of patient-derived cells; RT-PCR splicing analysis; tRNA quantification\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptome-wide profiling with orthogonal RT-PCR validation, single lab\",\n      \"pmids\": [\"27506977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A deep-intronic POLR3A mutation (c.1909+22G>A) activates a cryptic splice site in a tissue- and developmental stage-specific manner, establishing that non-coding/intronic variants in POLR3A reduce functional transcript levels in a tissue-specific fashion.\",\n      \"method\": \"RT-PCR and RNA splicing analysis; exome and targeted sequencing of cohort; segregation analysis\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — splicing demonstrated by RT-PCR with functional consequence, single lab but large cohort\",\n      \"pmids\": [\"28459997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Knock-in mice homozygous (KI/KI) or compound heterozygous (KI/KO) for the French Canadian founder Polr3a G672E mutation show no overt myelination defects and normal Pol III transcript levels in brain, demonstrating that this single mutation in mice is insufficient to recapitulate the human hypomyelinating phenotype.\",\n      \"method\": \"Knock-in mouse model; behavioral tests; Luxol Fast Blue myelin staining; myelin protein quantification; qRT-PCR of Pol III transcripts\",\n      \"journal\": \"Molecular brain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model with multiple orthogonal phenotyping methods (behavioral, histological, biochemical)\",\n      \"pmids\": [\"28407788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CRISPR-Cas9 introduction of the POLR3A c.2554A→G (p.M852V) mutation into human cell lines reduces Pol III transcriptional output, causes a global reduction in tRNA levels, and specifically down-regulates brain cytoplasmic BC200 RNA (BCYRN1); in POLR3A-mutant oligodendroglial cells, MBP mRNA levels are significantly decreased upon differentiation. Genomic BC200 deletion causes larger transcriptomic and proteomic changes than POLR3A mutation alone.\",\n      \"method\": \"CRISPR-Cas9 mutagenesis; transcriptomic profiling; RT-qPCR; proteomics; patient-derived fibroblasts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — CRISPR-engineered isogenic cell lines with multiple orthogonal methods (transcriptomics, proteomics, qPCR) and patient cell validation\",\n      \"pmids\": [\"30898877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Repression of Pol III transcription in S. cerevisiae under stress conditions leads to ubiquitylation of the largest Pol III subunit C160 (the yeast homolog of POLR3A/RPC1) and its subsequent proteasomal degradation, downstream of Pol III dissociation from chromatin. Blocking proteasomal degradation of C160 does not prevent proper transcriptional repression.\",\n      \"method\": \"Western blotting for C160 protein levels; detection of ubiquitylated C160; proteasome inhibitor treatment; chromatin occupancy assays; respiratory/rapamycin growth conditions\",\n      \"journal\": \"Biochimica et biophysica acta. Gene regulatory mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ubiquitylation detection, proteasome inhibition, chromatin occupancy) in yeast ortholog with clear functional context\",\n      \"pmids\": [\"30342998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HLD7-associated nonsense POLR3A mutation R140X causes the mutant protein to localize primarily as aggregates in lysosomes (rather than the nucleus as for wild-type protein), decreases mTOR signaling around lysosomes, and impairs oligodendroglial cell differentiation and myelin marker protein expression. Ibuprofen, an mTOR activator, partially rescues differentiation defects in cells expressing the R140X mutant.\",\n      \"method\": \"Fluorescence microscopy/confocal imaging; lysosome co-localization assay; mTOR signaling assays; oligodendroglial differentiation assay; myelin marker protein expression; ibuprofen treatment\",\n      \"journal\": \"Neurology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by confocal imaging linked to functional consequence (mTOR signaling, differentiation), single lab\",\n      \"pmids\": [\"35076634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HLD-causing missense mutations in POLR3A that cluster in the pore domain (which provides nucleotide access to the Pol III active site) were engineered into the yeast Rpc160 homolog; single mutations had no growth or transcription phenotype, but combining the pore mutations with a G672E mutation created double mutants with phenotypes ranging from wild-type to lethal. In the slowest-growing temperature-sensitive double mutant, global tRNA synthesis and RPR1/SNR52 RNA synthesis were compromised, and affinity-purified mutant Pol III showed defects in both factor-independent and factor-dependent transcription in vitro.\",\n      \"method\": \"Yeast genetics (engineered Rpc160 mutations); growth assays; in vitro transcription with affinity-purified Pol III; tRNA synthesis assays; RPR1/SNR52 RNA synthesis assays\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstituted transcription assay with purified mutant Pol III plus in vivo genetic analysis; multiple orthogonal methods; single lab\",\n      \"pmids\": [\"33148458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A POLR3A c.1771-6C>G splicing mutation causes aberrant splicing; in patient fibroblasts, expression levels of Pol III target genes (HNRNPH2, ubiquitin B, lactotransferrin, HSP90AA1) are decreased and are rescued to normal levels by overexpression of wild-type POLR3A but not by the p.Val1241Met variant, demonstrating that Val1241Met is a loss-of-function mutation affecting Pol III transcriptional activity.\",\n      \"method\": \"qRT-PCR; POLR3A overexpression rescue experiment in patient fibroblasts; RT-PCR for aberrant splicing\",\n      \"journal\": \"Neurology. Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — rescue experiment with wild-type vs mutant overexpression provides functional hierarchy; single lab\",\n      \"pmids\": [\"33134517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In WRS patient fibroblasts, a frameshift POLR3A mutation (c.3772_3773delCT) causes decreased wild-type POLR3A mRNA and protein, increased expression of the mutant protein, and increased nuclear localization of the mutant protein. These changes are associated with increased number/area of nucleoli, elevated pP53 and pH2AX signaling, and premature cellular senescence.\",\n      \"method\": \"RT-qPCR; immunoblotting; confocal microscopy for localization; SA-β-galactosidase senescence assay; immunofluorescence for pP53 and pH2AX\",\n      \"journal\": \"Mechanisms of ageing and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization and functional consequence assays in patient-derived cells, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32976914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Macrophage-derived DNA stimulates translocation of POLR3A from the nucleus to the perinuclear region near STING in fibroblasts and HUVECs, activating the POLR3A/STING/type I interferon response, monocyte adhesion, MCP-1 expression, and collagen overproduction. IRF3 (activated downstream of this pathway) directly binds the MCP-1 promoter. Knockdown of POLR3A or STING abolishes this response.\",\n      \"method\": \"Immunofluorescence/confocal microscopy for POLR3A subcellular localization; siRNA knockdown of POLR3A and STING; ChIP for IRF3 binding to MCP-1 promoter; Western blotting; STING knockout mouse model; bleomycin SSc mouse model\",\n      \"journal\": \"Rheumatology (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with functional consequence, ChIP, genetic knockdown and KO rescue; single lab\",\n      \"pmids\": [\"35686918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Overexpression of wild-type POLR3A significantly enhances Pol III transcription of 5S rRNA and tRNA Leu-CAA; a p.Cys767Phe mutant POLR3A, despite being expressed at higher levels than wild-type, fails to enhance Pol III transcription and instead reduces expression of POLR3A targets (BC200, tRNA Leu-CAA) and MBP/18S rRNA, demonstrating that the mutation causes a dominant-negative or loss-of-function effect on Pol III transcriptional activity.\",\n      \"method\": \"Cell transfection overexpression assay; RT-qPCR of Pol III target transcripts (5S rRNA, tRNA Leu-CAA, BC200, MBP, 18S rRNA)\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional overexpression assay with wild-type vs mutant comparison, multiple target transcripts; single lab\",\n      \"pmids\": [\"38561452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Overproduction of the N-terminal fragment of the largest Pol III subunit C160 (C160-NTF, yeast POLR3A homolog) suppresses the maf1Δ phenotype by decreasing tRNA transcription and Pol III occupancy on tRNA genes. C160-NTF alters interactions of C160 with C34 and C82 subunits of the C82-34-31 heterotrimer, suggesting that the N-terminal region of POLR3A mediates assembly of this Pol III subcomplex.\",\n      \"method\": \"Yeast genetics (overdose suppressor screen); ChIP for Pol III occupancy; tRNA synthesis assays (newly synthesized tRNA); co-immunoprecipitation of Pol III subunits (C160/C34/C82 interactions); HA-tag localization by microscopy\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic suppressor screen with mechanistic follow-up by ChIP, tRNA synthesis, and Co-IP for subunit interactions; multiple orthogonal methods\",\n      \"pmids\": [\"39142551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In WRS iPSCs carrying POLR3A mutations, POLR3A is upregulated during reprogramming; enhanced expression of mutant POLR3A leads to nucleolus abnormalities and sequestration of telomerase RNA component (TERC) in the nucleoli, establishing a functional link between POLR3A dysfunction, nucleolar structure, and telomerase RNA metabolism.\",\n      \"method\": \"iPSC reprogramming; immunofluorescence for nucleolar morphology; FISH/imaging for TERC localization in nucleoli\",\n      \"journal\": \"Biogerontology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct localization and functional consequence shown in iPSC model; single lab, single paper\",\n      \"pmids\": [\"41081995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"In zebrafish, loss of polr3a causes hypoplasia of neural crest cell-derived craniofacial cartilage and bone, reduced tRNA transcription, and reduced ribosome biogenesis. At larval stages, increased cell death occurs in craniofacial cartilage. Single-cell RNA-seq reveals upregulation of tp53, but Tp53 inhibition alone does not rescue craniofacial defects, indicating that additional downstream factors are required.\",\n      \"method\": \"Zebrafish polr3a mutant (loss-of-function); skeletal staining; cell death assays; tRNA transcription assays; ribosome biogenesis assays; single-cell RNA-seq; Tp53 inhibitor treatment\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods in loss-of-function vertebrate model (zebrafish KO), published as peer-reviewed full study\",\n      \"pmids\": [\"42258504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Monoallelic (heterozygous) missense POLR3A variants cause impaired Pol III activity in patient-derived cells, including mis-regulation of individual Pol III targets and global downregulation of tRNA pools, without changes in POLR3A expression, subcellular localization, or subunit interactions. The neuropathy-associated variants cluster in regions critical for Pol III catalytic activity and do not overlap with known biallelic disease-causing variants.\",\n      \"method\": \"Patient-derived cell transcriptomics; tRNA pool quantification; immunoblotting; subcellular fractionation; interactomics (subunit interaction assays); structural modelling\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (transcriptomics, interactomics, localization, structural modelling) in patient-derived cells; peer-reviewed publication\",\n      \"pmids\": [\"42260910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CRISPR-dCas13Rx targeting of POLR3A exon regions harboring disease-causing missense mutations reveals that ~20% of interrogated exon regions affect RNA splicing; minigene assays confirm that specific mutations (in exons 14 and 26) cause splicing aberrations. Antisense oligonucleotides (ASOs) targeting intronic elements identified by this approach rescue correct splicing of POLR3A in EcR293 and oligodendroglioma cell lines.\",\n      \"method\": \"CRISPR-dCas13Rx splicing interference; minigene splicing assays; antisense oligonucleotide (ASO) treatment; RT-PCR splicing analysis\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal functional assays (CRISPR-dCas13Rx, minigene, ASO rescue) establishing splicing mechanism; single lab\",\n      \"pmids\": [\"41732205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Progesterone receptor (PR) co-occupies ~50% of POLR3A-occupied tRNA genes upon progestin treatment, co-recruiting Maf1 to these sites. Maf1 knockdown significantly reduces progestin-induced tRNA transcription repression, establishing that PR-mediated repression of select tRNA genes by POLR3A requires Maf1 as a necessary effector.\",\n      \"method\": \"ChIP-seq for POLR3A, PR, Brf1 (TFIIIB), and Maf1; nascent tRNA transcription assays; Maf1 siRNA knockdown\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq with functional knockdown validation; preprint, single lab\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"POLR3A (RPC1/RPC155) encodes the largest catalytic subunit of RNA Polymerase III, forming the active center together with POLR3B; it is required for transcription of tRNAs, 5S rRNA, BC200 RNA, and other small non-coding RNAs essential for translation and cellular homeostasis. Disease-causing mutations reduce Pol III transcriptional output (globally decreasing tRNA pools and specific ncRNAs such as BC200), with some mutations causing aberrant splicing, lysosomal mislocalization with mTOR pathway disruption, or premature senescence with nucleolar abnormalities. Under stress, the yeast ortholog (C160) is ubiquitylated and degraded by the proteasome downstream of chromatin dissociation. The N-terminal domain of C160/POLR3A mediates assembly with the C82-34-31 heterotrimer. In the innate immune context, cytoplasmic DNA triggers perinuclear POLR3A relocalization to activate the STING/IRF3/type I interferon axis. In vivo, Polr3a loss in zebrafish reduces tRNA transcription and ribosome biogenesis, causing neural crest-derived craniofacial defects partly through tp53 upregulation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"POLR3A (RPC1/RPC155) encodes the largest catalytic subunit of RNA Polymerase III, which together with POLR3B forms the enzyme's active center responsible for transcribing tRNAs, 5S rRNA, BC200 (BCYRN1), and other small non-coding RNAs essential for translation and cellular homeostasis [#1, #5]. Its N-terminal region mediates assembly of the polymerase by engaging the C82-34-31 heterotrimer, and disease-clustered residues in the pore domain control nucleotide access to the catalytic site [#13, #8]. Recessive, monoallelic, and splice-altering POLR3A mutations converge on reduced Pol III output, depleting global tRNA pools and specific transcripts such as BC200, which impairs oligodendroglial differentiation and myelin marker expression; this links POLR3A to hypomyelinating leukodystrophy and to a distinct neuropathy caused by catalytic-region monoallelic variants [#5, #16, #0]. Beyond loss of catalytic output, individual mutations produce protein-level pathologies: a nonsense allele mislocalizes POLR3A to lysosomes and lowers peri-lysosomal mTOR signaling [#7], while frameshift mutations associated with Wiedemann-Rautenstrauch syndrome drive nuclear accumulation of mutant protein, nucleolar abnormalities with TERC sequestration, elevated p53/H2AX signaling, and premature senescence [#10, #14]. POLR3A also functions outside canonical transcription as a cytosolic DNA sensor: cytoplasmic DNA triggers its relocalization to perinuclear sites near STING, activating an IRF3-dependent type I interferon and pro-fibrotic response [#11]. In vivo, polr3a loss in zebrafish reduces tRNA transcription and ribosome biogenesis, causing tp53-associated neural crest craniofacial defects [#15].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Established that POLR3A is the largest catalytic subunit of Pol III and that its mutation reduces protein levels to impair CNS myelination, defining the gene as essential for the leukodystrophy phenotype.\",\n      \"evidence\": \"Immunoblotting of patient fibroblasts and autopsied brain; genetic mapping and Sanger sequencing across families\",\n      \"pmids\": [\"21855841\", \"22036171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the molecular mechanism linking reduced Pol III output to myelination\", \"Catalytic activity inferred from structure rather than reconstituted\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined POLR3A and POLR3B as jointly forming the Pol III active center, anchoring the enzyme's transcriptional activity.\",\n      \"evidence\": \"Genetic analysis of compound heterozygous mutations combined with structural inference\",\n      \"pmids\": [\"22036171\", \"21855841\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct in vitro catalytic reconstitution in these reports\", \"Subunit contributions to individual transcript classes not resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed that a splicing-deficient POLR3A founder allele reduces full-length transcript and depletes tRNAs and regulatory ncRNAs, extending impact to the Pol II transcriptome.\",\n      \"evidence\": \"RNA-seq of patient cells with RT-PCR splicing analysis and tRNA quantification\",\n      \"pmids\": [\"27506977\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Causal chain from ncRNA imbalance to disease not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated that intronic POLR3A variants reduce functional transcript in a tissue- and stage-specific manner, broadening the mutational spectrum beyond coding changes.\",\n      \"evidence\": \"RT-PCR splicing analysis and cohort exome/targeted sequencing with segregation\",\n      \"pmids\": [\"28459997\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specificity mechanism unresolved\", \"Quantitative threshold for disease not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Tested whether a single founder mutation suffices for disease in vivo; the knock-in mouse failed to recapitulate hypomyelination, revealing species- or allele-specific dependence.\",\n      \"evidence\": \"Polr3a G672E knock-in mouse with behavioral, histological, and biochemical phenotyping\",\n      \"pmids\": [\"28407788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not explain why human carriers develop disease\", \"Compound allele combinations not modeled\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided isogenic causal evidence that a POLR3A point mutation reduces Pol III output, depletes tRNAs and BC200, and lowers MBP upon oligodendroglial differentiation.\",\n      \"evidence\": \"CRISPR-engineered cell lines with transcriptomics, proteomics, qPCR, and patient cell validation\",\n      \"pmids\": [\"30898877\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each depleted ncRNA to myelination unresolved\", \"Did not address dominant vs recessive mechanism\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified post-transcriptional regulation of the largest subunit: under stress its yeast ortholog is ubiquitylated and proteasomally degraded after chromatin dissociation, separate from the repression event itself.\",\n      \"evidence\": \"Yeast Western blotting, ubiquitylation detection, proteasome inhibition, and chromatin occupancy assays\",\n      \"pmids\": [\"30342998\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase not identified\", \"Conservation of this turnover in human POLR3A untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapped disease mutations to the pore domain and showed via reconstituted transcription that combinations of mutations compromise both factor-independent and factor-dependent Pol III activity.\",\n      \"evidence\": \"Engineered yeast Rpc160 mutants, growth assays, and in vitro transcription with affinity-purified Pol III\",\n      \"pmids\": [\"33148458\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single mutations were phenotypically silent in yeast\", \"Direct translation to human catalytic defect inferred\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established a loss-of-function hierarchy by rescue, showing wild-type but not the p.Val1241Met POLR3A restores Pol III target gene expression.\",\n      \"evidence\": \"qRT-PCR and overexpression rescue in patient fibroblasts with RT-PCR splicing analysis\",\n      \"pmids\": [\"33134517\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Target genes assayed are a limited panel\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed a protein-mislocalization mechanism: a nonsense allele aggregates in lysosomes, lowers peri-lysosomal mTOR signaling, and impairs differentiation, with partial mTOR-activator rescue.\",\n      \"evidence\": \"Confocal lysosome co-localization, mTOR signaling assays, oligodendroglial differentiation, and ibuprofen treatment\",\n      \"pmids\": [\"35076634\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of lysosomal targeting unknown\", \"mTOR link based on a single mutant\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected POLR3A frameshift mutation to a senescence pathology, with nuclear accumulation of mutant protein, nucleolar expansion, and elevated p53/H2AX signaling.\",\n      \"evidence\": \"RT-qPCR, immunoblotting, confocal localization, SA-\\u03b2-gal, and pP53/pH2AX immunofluorescence in WRS fibroblasts\",\n      \"pmids\": [\"32976914\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link from nucleolar change to senescence not dissected\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Uncovered a non-transcriptional role: cytoplasmic DNA drives POLR3A perinuclear relocalization to STING, activating IRF3-dependent interferon and pro-fibrotic responses.\",\n      \"evidence\": \"Confocal localization, siRNA knockdown, IRF3 ChIP on the MCP-1 promoter, and STING-knockout/bleomycin mouse models\",\n      \"pmids\": [\"35686918\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of DNA recognition by POLR3A unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated that a missense mutant fails to enhance Pol III transcription despite higher expression, indicating a dominant-negative/loss-of-function effect on multiple targets.\",\n      \"evidence\": \"Overexpression transfection with RT-qPCR of 5S rRNA, tRNA Leu-CAA, BC200, MBP, and 18S rRNA\",\n      \"pmids\": [\"38561452\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dominant-negative versus loss-of-function not formally distinguished\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined the N-terminal region of the largest subunit as the assembly module that binds the C82-34-31 heterotrimer, linking its overproduction to altered tRNA gene occupancy.\",\n      \"evidence\": \"Yeast overdose suppressor screen, ChIP for Pol III occupancy, tRNA synthesis assays, and Co-IP of C160/C34/C82\",\n      \"pmids\": [\"39142551\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the N-terminal interaction not solved\", \"Human POLR3A assembly inferred from yeast\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed POLR3A within hormonal control of tRNA genes, showing PR co-occupancy and Maf1 co-recruitment are required for progestin-induced tRNA repression.\",\n      \"evidence\": \"ChIP-seq for POLR3A/PR/Brf1/Maf1 with nascent tRNA assays and Maf1 knockdown (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, single lab\", \"Direct PR-POLR3A contact not demonstrated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linked POLR3A dysfunction to telomerase RNA metabolism, showing mutant protein causes nucleolar abnormalities and sequesters TERC in nucleoli.\",\n      \"evidence\": \"WRS iPSC reprogramming with nucleolar immunofluorescence and TERC FISH imaging\",\n      \"pmids\": [\"41081995\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of TERC sequestration for telomerase activity untested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined a distinct monoallelic neuropathy mechanism: catalytic-region variants impair Pol III activity and deplete tRNAs without altering POLR3A expression, localization, or subunit interactions.\",\n      \"evidence\": \"Patient-cell transcriptomics, tRNA quantification, fractionation, interactomics, and structural modelling\",\n      \"pmids\": [\"42260910\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How catalytic depletion produces peripheral rather than central pathology unresolved\", \"Specific affected tRNA isoacceptors not fully mapped\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Established polr3a loss in a vertebrate causes neural-crest craniofacial defects via reduced tRNA transcription and ribosome biogenesis, with tp53 upregulation insufficient to explain the phenotype.\",\n      \"evidence\": \"Zebrafish loss-of-function mutant with skeletal staining, cell death and ribosome assays, scRNA-seq, and Tp53 inhibition\",\n      \"pmids\": [\"42258504\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Additional downstream effectors beyond tp53 unidentified\", \"Cell-type specificity of vulnerability unresolved\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Demonstrated a therapeutic splicing-correction strategy, identifying mutation-induced splicing aberrations and rescuing them with antisense oligonucleotides.\",\n      \"evidence\": \"CRISPR-dCas13Rx splicing interference, minigene assays, and ASO rescue with RT-PCR\",\n      \"pmids\": [\"41732205\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy not demonstrated\", \"Fraction of disease alleles amenable to ASO correction unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How distinct POLR3A mutations produce divergent tissue phenotypes (hypomyelination, neuropathy, progeroid senescence, craniofacial defects) from a shared reduction in Pol III output remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking specific tRNA/ncRNA deficits to specific tissue vulnerabilities\", \"Genotype-phenotype rules for coding vs splice vs mislocalizing alleles undefined\", \"Mechanism of the non-canonical DNA-sensing role versus the transcriptional role not integrated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [1, 5, 8, 16]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 8, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [7, 10, 11]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [10, 14]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 5, 8]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [2, 5, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"complexes\": [\"RNA Polymerase III\"],\n    \"partners\": [\"POLR3B\", \"POLR3F\", \"POLR3H\", \"POLR3G\", \"MAF1\", \"STING1\", \"PGR\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":6,"faith_total":6,"faith_pct":100.0}}